Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
Keith J. Chappell(Australian Research Council), Trent P. Munro(The University of Queensland)
Cited by 119
Related Papers
Accelerating patient access to novel biologics using stable pool‐derived product for non‐clinical studies and single clone‐derived product for clinical studies
|Biotechnology Progress|2017|35
Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine
|Frontiers in Immunology|2022|17